Navigation Links
Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC)
Date:4/26/2008

Genomics improves our ability to target experimental cancer treatments

A promising new drug is in hand, and more are on the way

Improved ability to select patients to test particular drugs

MILAN, Italy, April 27 /PRNewswire/ --

At today's sessions of this, the final day of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), leading hepatologists described several important advances in understanding and provide novel treatments for hepatocellular carcinoma (HCC). Most notably, progress has been made by acquiring data that improve our understanding of the disease process at the molecular level... what is taking place in the body that leads to the development of HCC.

Applying the technologies of genomics and microarrays, scientists have discovered that there are a number of different biological pathways that result in HCC. Using this knowledge, they can now classify and explore various subtypes of HCC. This novel view contradicts the previous belief that the disease occurs in one way only, from a single disease mechanism.

The discovery of subtypes has significant implications. First, it raises the possibility of targeting treatments to particular patients, based on their respective cancer subtype ("targeted therapeutics"). Second, it enables more precise assessment of the response to specific experimental therapies. Moreover, it offers the possibility of refining each patient's prognosis, again based on his or her cancer subtype.

Malignancy is a complex process. It involves the accumulation of multiple independent gene mutations that lead to deregulation of cell pathways that influence cell growth and cell fate. The process itself is called the "oncogenic pathway." In the past, most scientists in the field believed that there was only one oncogenic "pathway" in HCC.

HCC is one of the most common tumors worldwide. Most cases of HCC result from a viral infection (Hepa
'/>"/>

SOURCE EASL - European Association for the Study of the Liver
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
4. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
5. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
6. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
7. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
8. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
9. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
10. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Dec. 1 At this year,s annual meet...RSNA), Royal Philips Electronics ( PHG, AEX: PHI) ...t of solutions that provides radiologists the abil...workspot to help drive quality and efficiency. Sh...ll also highlight new capabilities for its portfol...
(Date:12/1/2009)...Dec. 1 ADVENTRX Pharmace...hat a new, recently completed preclinical study ha...ity of ANX-514 and Taxotere® (docetaxel). Sh...NX-514 in South Korea, independently conducted the... confirmation of the bioequivalence and comparable...
(Date:12/1/2009)...CITY, Calif., Dec. 1 Codexis, Inc....and the signing of its second agreement this year ...d,s largest generic drug manufacturer. The new ag...oducts. Codexis announced an earlier agreement wi...t, Teva will use Codexis biocatalysis technology f...
Breaking Medicine Technology:Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Codexis Expands Collaboration with Teva 2Cogdell Spencer Inc Declares Quarterly Dividend 48744 1Cogdell Spencer Inc Declares Quarterly Dividend 48744 2Kaiser Permanente Community Benefit Grant Recipient and Health Activist Rosa Soto Featured in Food Inc Documentary Film 48741 1Kaiser Permanente Community Benefit Grant Recipient and Health Activist Rosa Soto Featured in Food Inc Documentary Film 48741 2Kaiser Permanente Community Benefit Grant Recipient and Health Activist Rosa Soto Featured in Food Inc Documentary Film 48741 3DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 1DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 3
...ust their function like a radio dial, not an on/of...immune disease may develop,late in life, MEMPHIS,...pital study shows that T cells, the body,s master ...es to govern the cellular,machinery that regulates...ess sophisticated molecular controls that enable t...
...May 12 Arbios Systems, Inc.,(OTC Bulletin Board: ...d,approval from the U.S. Food and Drug Administrat... ("IDE") to begin the pivotal clinical,trial for S...) liver assist,device for blood purification of ac...sease., "We are pleased to have received FDA appr...
Other Medicine Technology:St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5
(Date:12/1/2009)..., WASHINGTON, Dec. 1 ...soners and 1,538 federal prisoners were HIV positi...atistics (BJS) in the Office of Justice Programs, ...arend 2008, an estimated 5,672 inmates in state an...762 in 2007. In 2007, about 43 per 10,000 prison i...
(Date:12/1/2009)...fy those who would benefit from liver surgery afte... 1 (HealthDay News) -- A CT scan of liver tumors c...predict overall survival after chemotherapy, resea...o cytotoxic chemotherapy has been shown to improve...ancer and to produce better results in patients ha...
(Date:12/1/2009)... Practitioners of any medical, legal ...are breathing a sigh of relief this week with the ... application, released over the holiday weekend, a...ice recordings to do so quickly and seamlessly usi... (PRWEB) December 1, 2009 -- The iPhone App,...
(Date:12/1/2009)... , ,, NEW YORK, Dec. 1 /PRNewswire/ ...l leader in the development and delivery of custom...ical, scientific and academic markets, will be sho...ch, our first-to-market cross-platform search solu...exicon, based on the American Psychological Associ...
(Date:12/1/2009)..., FORT LAUDERDALE, Fla., Dec. 1 Or... enrollment in the randomized clinical trial of th...mbo Stent). ,, A prospective, randomized, multi...on of an ablu M inal sirolimus coat ED bio- ...t up to 20 sites in Asia, Australia, Europe and So...
Breaking Medicine News(10 mins):Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 2Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 3Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4
...vailable in German . , One of the defining cha...ically prevent programmed cell death (apoptosis), ...iferation of defective cells. In order to do this,...s, since if the levels of IAPs are reduced, tumour...
...n NPAF,s National Legislative Team, Response to Is... , WASHINGTON, Dec. 1 The National Patient Adv...organization dedicated to the mission of creating ...ayson Fowler to Vice President of Federal Legislat...
... your orthopaedic surgeon is the driving force for...Ill., Dec. 1 /PRNewswire-USNewswire/ - - While ma... any musculoskeletal injury may be anxious to get ... the concerns of orthopaedic surgeons and patients...
...ecember 1 Mentice proudly announces,the launch of...ning - the,Mentice VIST 7.7 enhanced training modu...atures such as vital signs, complications, medicat...ike vital signs and complications imply a dynamic ...
...008 -- 11 a.m. news event -- Hall of States, Room ...C 20001 , , WASHINGTON, Dec. 1 The nation,s ...r to outline the current fiscal situation states a...ase the burden of Medicaid costs. As many states f...
...Two individuals associated with Vinson,Hall Retire... the Pearl Harbor,attack, will participate in a co...t the U.S. Navy Memorial in Washington, D.C. One ...ethods and technologies,for serving seniors. , ...
Other Medicine News:Health News:Surprise discovery made in cancer research 2Health News:National Patient Advocate Foundation (NPAF) Announces New Executive Vice President of Federal Legislative Affairs 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 3Health News:Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level 2Health News:Governors, Legislators Update Current State Fiscal Conditions, Push for Economic Recovery Package from Congress, President-elect 2Health News:Individuals Associated with Vinson Hall Retirement Community, Who Survived Pearl Harbor Attack, to Participate in Navy Memorial Event December 7 2
Shoulder Subluxation Inhibitor (SSI)
Comfor™ Shoulder Immobilizer - Universal
...s a critical component of pain relief, functional ...en® Lumbosacral Bracing System™ offers t...vide a high degree of immobilization, unparalled c... . . . even if they gain or lose weight. It combin...
Shoulder Immobilizer with Body Strap
Medicine Products: